^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Columvi (glofitamab-gxbm)

    i
    Other names: RG6026, RO7082859, CD20 TCB, RG 6026, RO-7082859, RO 7082859, anti-CD20 CD3 TCB, RG-6026
    Company:
    Biogen, Roche
    Drug class:
    CD20 inhibitor, CD3 agonist
    Related drugs:
    2d
    AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Truxima (rituximab-abbs) • Columvi (glofitamab-gxbm) • Mabtas (rituximab biosimilar)
    3d
    NCI-2024-00209: A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma (clinicaltrials.gov)
    P2, N=40, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2027 --> Jul 2027 | Trial primary completion date: Jan 2027 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • Columvi (glofitamab-gxbm)
    7d
    Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL (clinicaltrials.gov)
    P1/2, N=46, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P1/2 trial
    |
    Columvi (glofitamab-gxbm)
    8d
    Beyond Chemoimmunotherapy: Emerging Cellular and Targeted Therapies in Transformed Follicular Lymphoma: A Scoping Review. (PubMed, Cancer Control)
    CAR-T products achieved overall response rates (ORR) of 52-83% and complete response (CR) rates of 40-58%; randomized second-line trials favored axicabtagene ciloleucel and lisocabtagene maraleucel over standard care...BsAbs were active in heavily pretreated disease (epcoritamab ORR 50%/CR 44%; glofitamab ORR 55%/CR 35%), with predominantly low-grade cytokine release syndrome. Selinexor showed more modest efficacy (ORR 39%/CR 16%) but durable benefit in complete responders.ConclusionsCurrent evidence supports a stepwise treatment framework: DLBCL-like induction at transformation, autologous stem-cell transplant in fit, chemosensitive responders, CAR-T as the preferred option at first relapse, BsAbs after CAR-T or when cellular therapy is not feasible, and selinexor in later-lines of therapy. Additional prospective t-FL-inclusive trials are needed to refine treatment selection and biomarker-guided sequencing.
    Review • Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Xpovio (selinexor) • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Epkinly (epcoritamab-bysp) • Columvi (glofitamab-gxbm)
    11d
    Radio-GLO: Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Olivia Newton-John Cancer Research Institute
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • IL4 (Interleukin 4)
    |
    Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)
    14d
    REBEL: External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Utah | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Epkinly (epcoritamab-bysp) • Columvi (glofitamab-gxbm)
    15d
    Glofitamab in Real Life (clinicaltrials.gov)
    P=N/A, N=250, Recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Jul 2026 --> Dec 2026
    Trial completion date
    |
    Columvi (glofitamab-gxbm)
    21d
    Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    TP53 (Tumor protein P53)
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • Columvi (glofitamab-gxbm)
    23d
    UPCC 48420: CAR-T Followed by Bispecific Antibodies (clinicaltrials.gov)
    P2, N=23, Recruiting, Abramson Cancer Center at Penn Medicine | N=42 --> 23
    Enrollment change
    |
    Gazyva (obinutuzumab) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm)
    24d
    Case Report: Neurolymphomatosis of the sciatic nerve as a presentation of relapsed diffuse large B-cell lymphoma. (PubMed, Front Oncol)
    A 71-year-old man with systemic diffuse large B-cell lymphoma (DLBCL), histologically confirmed by gastric biopsy, developed progressive left-leg neuropathic pain, numbness, and foot drop during rituximab maintenance after achieving complete remission (CR)...Given the patient's age and risk of neurotoxicity, treatment with cyclophosphamide preconditioning followed by glofitamab plus obinutuzumab achieved rapid clinical improvement and partial remission (PR) on imaging...In this case, nerve US played a central role by demonstrating the characteristic "fried egg sign," localizing the lesion, and enabling US-CNB for tissue confirmation, while contrast-enhanced MRI and whole-body ^18F-FDG PET/CT provided complementary information on neural involvement and overall disease extent. An ultrasound-centered multimodal approach may help shorten time to diagnosis and facilitate timely treatment and neurological recovery.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • cyclophosphamide • Columvi (glofitamab-gxbm)
    27d
    LME-Guided Precision Combination Therapy in B-cell Lymphoma Patients After CD19 CAR-T Failure (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Venclexta (venetoclax) • Tevimbra (tislelizumab-jsgr) • Columvi (glofitamab-gxbm)
    29d
    A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=96, Not yet recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    gemcitabine • Gazyva (obinutuzumab) • oxaliplatin • Columvi (glofitamab-gxbm)